Rendu Bio released its 2026 interim report on August 29, 2026. During the reporting period, the company's total operating revenue was 79.4374 million yuan, down 2.22% year on year; net profit attributable to the parent company was 9.5755 million yuan. Net cash flow from operating activities was negative 2.0549 million yuan, a decrease of 1.013 million yuan compared with the same period last year. The company's asset-liability ratio was 6.79%, gross margin was 78.81%, return on equity was 1.08%, and diluted earnings per share was 0.27 yuan. The number of shareholders was 3,482, and the top ten shareholders held 58.29% of the total share capital.
Shanghai Rendu Biotechnology Co. Ltd. ARevenue declined 2.22% YoY and operating cash flow turned negative, indicating weaker financial performance.